TY - JOUR
T1 - Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel
AU - Zee, Phyllis C.
AU - Wang-Weigand, Sherry
AU - Wright, Kenneth P.
AU - Peng, Xuejun
AU - Roth, Thomas
N1 - Funding Information:
Assistance with writing and manuscript preparation was provided by Sara Sarkey, PhD, an employee of Takeda Pharmaceuticals North America. This study was funded by the Takeda Pharmaceutical Company Ltd.
Funding Information:
Kenneth P. Wright Jr. has received consulting fees, speaker’s fees, clinical trial research contracts and investigator-initiated research grants from Cephalon Inc.; has received consulting fees, speakers fees, investigator-initiated research Grants and education Grants from Takeda Pharmaceuticals North America; serves on the advisory board for Zeo Inc. (formerly Axon Labs Inc.) and receives Nonqualified Stock Options.
Funding Information:
Thomas Roth has received grant funding from Aventis, Cephalon, GlaxoSmithKline, Merck, Neurocrine, Pfizer, Sanofi, scheringPlough, Sepracor, Somaxon, Cyrex, Takeda, TransOral, Wyeth, and Xenoport. He has been a consultant for Abbott, Acadia, Acologix, Acorda, Actelion, Addrenex, Alchemers, Alza, Ancel, Arena, AstraZeneca, Aventis, AVER, Bayer, BMS, BTG, Cephalon, Cypress, Dove, Eisai, Elan, Eli Lilly, Evotec, Forest, GlaxoSmithKline, Hypnion, Impax, Intec, Intra-Cellular, Jazz, Johnson and Johnson, King, Lundbeck, McNeil, MediciNova, Merck, Neurim, Neurocrine, Neurogen, Novartis, Orexo, Organon, Otsuka, Prestwick, Proctor and Gamble, Pfizer, Purdue, Resteva, Roche, Sanofi, Schering-Plough, Sepracor, Servier, Shire, Somaxon, Cyrex, Takeda, TransOral, Vanda, Vivometrics, Wyeth, Yamanouchi, and Xenoport. He has participated in speaking arrangements for Cephalon and Sanofi.
PY - 2010/6
Y1 - 2010/6
N2 - Objective: Ramelteon, an MT1/MT2 melatonin receptor agonist, was evaluated for its ability to reduce sleep-onset difficulties associated with eastward jet travel. Methods: Healthy adults (n= 110) with a history of jet lag sleep disturbances were flown eastward across five time zones from Hawaii to the east coast of the US. Ramelteon 1, 4, or 8. mg or placebo was administered 5. min before bedtime (local time) for four nights. Sleep parameters were measured using polysomnography (PSG) on Nights 2, 3, and 4. Next-day residual effects were assessed using psychomotor and memory function tests. Results: Compared to placebo, there was a significant decrease in mean latency to persistent sleep (LPS) on Nights 2-4 with ramelteon 1. mg (-10.64. min, P= 0.030). No consistent significant differences were observed with ramelteon vs. placebo on measures of next-day residual effects except on Day 4 where participants in all ramelteon groups performed significantly worse on the immediate memory recall test compared with placebo (P≤ 0.05). The incidence of adverse events was similar for ramelteon and placebo. Conclusion: After a 5-h phase advance due to eastward jet travel, ramelteon 1. mg taken before bedtime for four nights reduced mean LPS relative to placebo in healthy adults.
AB - Objective: Ramelteon, an MT1/MT2 melatonin receptor agonist, was evaluated for its ability to reduce sleep-onset difficulties associated with eastward jet travel. Methods: Healthy adults (n= 110) with a history of jet lag sleep disturbances were flown eastward across five time zones from Hawaii to the east coast of the US. Ramelteon 1, 4, or 8. mg or placebo was administered 5. min before bedtime (local time) for four nights. Sleep parameters were measured using polysomnography (PSG) on Nights 2, 3, and 4. Next-day residual effects were assessed using psychomotor and memory function tests. Results: Compared to placebo, there was a significant decrease in mean latency to persistent sleep (LPS) on Nights 2-4 with ramelteon 1. mg (-10.64. min, P= 0.030). No consistent significant differences were observed with ramelteon vs. placebo on measures of next-day residual effects except on Day 4 where participants in all ramelteon groups performed significantly worse on the immediate memory recall test compared with placebo (P≤ 0.05). The incidence of adverse events was similar for ramelteon and placebo. Conclusion: After a 5-h phase advance due to eastward jet travel, ramelteon 1. mg taken before bedtime for four nights reduced mean LPS relative to placebo in healthy adults.
KW - Eastward travel
KW - Jet lag
KW - Latency to persistent sleep
KW - Melatonin receptor agonist
KW - Phase-shift
KW - Polysomnography
UR - http://www.scopus.com/inward/record.url?scp=77953360884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953360884&partnerID=8YFLogxK
U2 - 10.1016/j.sleep.2010.03.010
DO - 10.1016/j.sleep.2010.03.010
M3 - Article
C2 - 20483660
AN - SCOPUS:77953360884
SN - 1389-9457
VL - 11
SP - 525
EP - 533
JO - Sleep Medicine
JF - Sleep Medicine
IS - 6
ER -